FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

Operator Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Between July and September, Abrysvo brought Pfizer $356 million in sales globally, compared to last year’s total of $375 million, according to third quarter earnings Pfizer reported Tuesday.

A solid showing for HIV drugs sold by majority-owned ViiV Healthcare and speciality medicines like cancer therapies Zejula ...

As fall approaches, so does respiratory syncytial virus or RSV season. This year, there are more options for those most ...